Gene marker combination for predicting cancer prognosis, kit, system and application

By analyzing transcriptomic data from ESCC patients, gene markers such as CD8A, CD79A, and CXCL9 were identified, and a prognostic assessment model was established. This solved the problem of low efficacy of immunotherapy in ESCC patients and enabled more accurate prognostic assessment and treatment guidance.

CN121428092APending Publication Date: 2026-01-30THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511167083.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-20
Publication Date
2026-01-30

AI Technical Summary

Technical Problem

In the current technology, immunotherapy for patients with esophageal squamous cell carcinoma (ESCC) has low efficacy and lacks effective prognostic biomarkers to guide the selection of treatment options.

Method used

By analyzing transcriptome data from the GEO and TCGA databases, we identified the types of immune-infiltrating cells in the TME, used unsupervised hierarchical clustering to identify key prognostic immune molecules, established a molecular prognostic and immunotherapy efficacy prediction model, and used the combination of gene markers CD8A, CD79A, and CXCL9 for prognostic assessment.

Benefits of technology

It improves the accuracy of cancer prognostic assessment, can effectively predict immunotherapy response, provides precision treatment guidance for ESCC patients, and improves treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121428092A_ABST
    Figure CN121428092A_ABST
Patent Text Reader

Abstract

The invention discloses a gene marker combination for predicting cancer prognosis, a kit, a system and application, and belongs to the technical field of medical molecular biology. Wherein the gene marker combination is prepared from CD8A, CD79A and CXCL9 (CXCL9). According to the gene marker combination, the kit and the system, cancer prognosis can be accurately evaluated by constructing a risk prediction model, the accuracy is high, and the gene marker combination, the kit and the system have very important clinical application value. In addition, the gene marker combination, the kit and the system can also be used for predicting immunotherapy response, a new detection target is provided for cancer treatment, and precise treatment can be achieved.
Need to check novelty before this filing date? Find Prior Art